BMRA: Biomerica, Inc Projected Sales Volume

Corporate company logo of Biomerica, Inc. (BMRA)

Risks for Biomerica, Inc. (BMRA) are linked to a dependence on partner networks and M&A transactions. The estimated sales volume of the firm, as displayed by the GURU.Markets platform, has stabilized at 0.00, confirming volatility. Stability is provided by the contract manufacturing of test systems, external IT solutions for transmitting diagnoses, and the outsourcing of logistics to third-party services, while high-tech analysis remains an internal asset of the company.

Company Expected Sales Volume: Biomerica, Inc. (BMRA) for 07/04/2022 - 11/18/2026

Summary analytical data breakdowns for Biomerica Inc (BMRA)

- stock quotes and analyst forecast:
Fundamental valuation:Biomerica Inc.
Brand item of Biomerica, Inc

Biomerica, Inc. is scaling access to early gastrointestinal cancer diagnostics through pharmacy chains. This sales benchmark for the company reflects the implementation dynamics of non-invasive tests. The metric measures the operational return on commercial strategies, converting market demand into projected revenue volume. Growth in the line confirms distribution efficiency, while a decline signals product stagnation. Trend analysis allows for an assessment of the risk of capital freeze in current projects.

Main competitors

Company Projected Revenue Agilent (A)|Projected Sales Volume Quest Diagnostics Incorporated (DGX)|Company Projected Revenue Illumina Corp ILMN|EXAS: Company Revenue Forecast|RVTY: Company Future Sales Volume|Company Sales Forecast bio-rad.com (BIO)|NNNN: Projected Sales Volume|Sotera Health - Company Future Revenue|QDEL (quidel.com) - Projected Sales Volume|OPK: Company Future Revenue|Company Future Sales Volume CDNA (CareDx)|Projected Sales Volume Maravai LifeSciences (MRVI)|Fulgent Genetics, Inc. - Company Future Sales Volume|LAB: Company Revenue Forecast|Cytek Corp - Projected Sales Volume|Company Future Revenue OSUR (OraSure Technologies)|XGN: Projected Sales Volume|MDxHealth - Company Future Revenue|LUCD (luciddx.com) - Projected Sales Volume|PRE - Company Sales Forecast|Company Projected Revenue Insight Molecular Diagnostics Inc (IMDX)|TRIB - Company Expected Sales Volume|Projected Sales Volume PRPH (ProPhase Labs, Inc.)|Company Future Sales ainos.com (AIMD)|Co-Diagnostics Inc - Projected Sales Volume|HSCS - Projected Sales Volume|Cardio Diagnostics (CDIO) - Company Projected Revenue|ONCO - Company Future Sales|VRAX (Virax Biolabs Corp) - Projected Sales Volume|Bluejay Diagnostics, Inc. (BJDX) - Company Future Sales|Projected Sales Volume AWH|Accelerate Diagnostics Inc. - Company Revenue Forecast|Centogene - Company Future Sales Volume|Enzo Biochem, Inc. (ENZ) - Company Expected Sales Volume|Company Projected Revenue Volume Fresh2 Group Limited FRES|Company Future Sales gtglabs.com GENE|23andMe Holding Co (ME) - Company Projected Revenue|Company Revenue Forecast PMD